Literature DB >> 318657

Antinuclear antibody with distinct specificity for polymyositis.

J F Wolfe, E Adelstein, G C Sharp.   

Abstract

In the course of studying antinuclear antibodies in the rheumatic diseases, a new precipitin reaction (provisionally referred to as PM-1) was observed between calf thymus nuclear extract and polymyositis sera. Objectives of this study were to further define the immunologic nature of this reaction and to determine its specificity for polymyositis. Immunodiffusion studies using calf thymus nuclear extract revealed the PM-1 precipitin line in 17 of 28 patients with polymyositis. This reaction was not produced by sera of 460 patients with other diseases. Enzyme and heat treatments of the nuclear extract showed that PM-1 was distinct from native DNA, ribonucleoprotein, and Sm antigens. Fractionation of PM-1-positive serum by 30% ammonium sulphate and Sephadex G-200 chromatography revealed that the factor producing the PM-1 precipitin reaction was in a serum fraction which showed only IgG by immunoelectrphoresis against anti-whole human serum. Because of the apparent strong specificity, the PM-1 system may represent a marker antibody for polymyositis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 318657      PMCID: PMC333345          DOI: 10.1172/JCI108616

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  6 in total

1.  A clinical study of serum antinuclear factor.

Authors:  D M WEIR; E J HOLBOROW; G D JOHNSON
Journal:  Br Med J       Date:  1961-04-01

2.  Description of a serological reaction characteristic of polymyositis.

Authors:  M Reichlin; M Mattioli
Journal:  Clin Immunol Immunopathol       Date:  1976-01

3.  Rheumatic disease sera reactive with capillaries in the mouse kidney.

Authors:  E M Tan; C M Pearson
Journal:  Arthritis Rheum       Date:  1972 Jan-Feb

4.  Circulating antibodies in polymyositis.

Authors:  G M Stern; A L Rose; K Jacobs
Journal:  J Neurol Sci       Date:  1967 Jul-Aug       Impact factor: 3.181

5.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

6.  Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy.

Authors:  G C Sharp; W S Irvin; R L LaRoque; C Velez; V Daly; A D Kaiser; H R Holman
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808

  6 in total
  39 in total

1.  Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen.

Authors:  Q Ge; M B Frank; C O'Brien; I N Targoff
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 2.  Antinucleic acid antibodies.

Authors:  E J Holborow
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 3.  Systemic diseases and the detection of antinuclear and anticytoplasmic antibodies. An historical review.

Authors:  M Walravens
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

4.  Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA).

Authors:  A Gaudreau; B Amor; M F Kahn; A Ryckewaert; J Sany; A P Peltier
Journal:  Ann Rheum Dis       Date:  1978-08       Impact factor: 19.103

Review 5.  Recent advances in polymyositis.

Authors:  W M Behan; P O Behan
Journal:  Ital J Neurol Sci       Date:  1984-03

6.  Familial canine dermatomyositis. Initial characterization of the cutaneous and muscular lesions.

Authors:  A M Hargis; K H Haupt; G A Hegreberg; D J Prieur; M P Moore
Journal:  Am J Pathol       Date:  1984-08       Impact factor: 4.307

7.  Experimental autoimmune myositis in SJL/J mice.

Authors:  N L Rosenberg; S P Ringel; B L Kotzin
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

8.  Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes.

Authors:  M Reichlin; P J Maddison; I Targoff; T Bunch; F Arnett; G Sharp; E Treadwell; E M Tan
Journal:  J Clin Immunol       Date:  1984-01       Impact factor: 8.317

9.  Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap.

Authors:  T Mimori; M Akizuki; H Yamagata; S Inada; S Yoshida; M Homma
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

10.  Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group.

Authors:  A El-Ghobarey; G Balint; K de Ceulaer; W C Dick; W W Buchanan; T Hadidi; T A Hassan
Journal:  Postgrad Med J       Date:  1978-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.